Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review)
- Authors:
- Li-Hua Shao
- Li Zhu
- Meng Wang
- Yue Ning
- Feng-Qin Chen
- Xia-Qing Gao
- Chun-Ting Yang
- Hong-Wei Wang
- Hai-Long Li
-
Affiliations: Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, P.R. China, Emergency Department, Minda Hospital of Hubei Minzu University, Enshi, Hubei 445000, P.R. China, Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730000, P.R. China, Department of Clinical Laboratory, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou, Gansu 730050, P.R. China - Published online on: June 29, 2023 https://doi.org/10.3892/ijmm.2023.5272
- Article Number: 69
-
Copyright: © Shao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A and Levine H: Hybrid Epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther. 194:161–184. 2019. View Article : Google Scholar | |
|
Phan TG and Croucher PI: The dormant cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jenkins RW, Barbie DA and Flaherty KT: Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118:9–16. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez JS and Banerji U: Combine and conquer: Challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 14:57–66. 2017. View Article : Google Scholar | |
|
Wilczyński JR, Wilczyński M and Paradowska E: Cancer stem cells in ovarian cancer-a source of tumor success and a challenging target for novel therapies. Int J Mol Sci. 23:24962022. View Article : Google Scholar | |
|
Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR and Vasconcelos MH: The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 46:1006452019. View Article : Google Scholar : PubMed/NCBI | |
|
Schoenfeld AJ and Hellmann MD: Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 37:443–455. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Aleksakhina SN, Kashyap A and Imyanitov EN: Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 1872:1883102019. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Y, Feng SL, He F, Yan PY, Yao XJ, Fan XX, Leung EL and Zhou H: Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. Pharmacol Res. 186:1065142022. View Article : Google Scholar : PubMed/NCBI | |
|
Makena MR, Ranjan A, Thirumala V and Reddy AP: Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. Biochim Biophys Acta Mol Basis Dis. 1866:1653392020. View Article : Google Scholar | |
|
Erin N, Grahovac J, Brozovic A and Efferth T: Tumor micro-environment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 53:1007152020. View Article : Google Scholar | |
|
Gourley C, Balmaña J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E and Boulton SJ: Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 37:2257–2269. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, et al: Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut. 71:1277–1288. 2022. View Article : Google Scholar | |
|
Carneiro BA and El-Deiry WS: Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A and Jaitak V: Natural products as multidrug resistance modulators in cancer. Eur J Med Chem. 176:268–291. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lai JI, Tseng YJ, Chen MH, Huang CF and Chang PM: Clinical perspective of FDA approved drugs with P-Glycoprotein inhibition activities for potential cancer therapeutics. Front Oncol. 10:5619362020. View Article : Google Scholar : PubMed/NCBI | |
|
Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Zhang J, Zhang M, Song Y, Zhang Y, Fan S, Ren S, Fu L, Zhang N, Hui H, et al: Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clin Transl Med. 11:e5772021. View Article : Google Scholar | |
|
Zhai K, Mazurakova A, Koklesova L, Kubatka P and Büsselberg D: Flavonoids synergistically enhance the anti-glioblastoma effects of chemotherapeutic drugs. Biomolecules. 11:18412021. View Article : Google Scholar : PubMed/NCBI | |
|
He XL, Xu XH, Shi JJ, Huang M, Wang Y, Chen X and Lu JJ: Anticancer effects of ginsenoside Rh2: A systematic review. Curr Mol Pharmacol. 15:179–189. 2022. | |
|
Wang Y, Xu J, Wang Y, Xiang L and He X: S-20, a steroidal saponin from the berries of black nightshade, exerts anti-multidrug resistance activity in K562/ADR cells through autophagic cell death and ERK activation. Food Funct. 13:2200–2215. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tilaoui M, Ait Mouse H and Zyad A: Update and new insights on future cancer drug candidates from plant-based alkaloids. Front Pharmacol. 12:7196942021. View Article : Google Scholar : | |
|
Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A and Yousefi B: Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. IUBMB Life. 72:855–871. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, He D, Zhang E, Chen J, Chen Q, Li Y, Yang L, Yang Y, Zhao Y, Wang G, et al: HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair. J Exp Clin Cancer Res. 37:2052018. View Article : Google Scholar : PubMed/NCBI | |
|
Borde C, Dillard C, L'Honoré A, Quignon F, Hamon M, Marchand CH, Faccion RS, Costa MGS, Pramil E, Larsen AK, et al: The C-terminal acidic tail modulates the anti-cancer properties of HMGB1. Int J Mol Sci. 23:78652022. View Article : Google Scholar | |
|
Gaikwad S, Puangmalai N, Bittar A, Montalbano M, Garcia S, McAllen S, Bhatt N, Sonawane M, Sengupta U and Kayed R: Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia. Cell Rep. 36:1094192021. View Article : Google Scholar : PubMed/NCBI | |
|
Stros M: HMGB proteins: Interactions with DNA and chromatin. Biochim Biophys Acta. 1799:101–113. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wen B, Wei YT and Zhao K: The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance. Mol Cell Biochem. 476:1729–1739. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Voong CK, Goodrich JA and Kugel JF: Interactions of HMGB Proteins with the Genome and the Impact on Disease. Biomolecules. 11:14512021. View Article : Google Scholar : PubMed/NCBI | |
|
Catena R, Escoffier E, Caron C, Khochbin S, Martianov I and Davidson I: HMGB4, a novel member of the HMGB family, is preferentially expressed in the mouse testis and localizes to the basal pole of elongating spermatids. Biol Reprod. 80:358–366. 2009. View Article : Google Scholar | |
|
Niu L, Yang W, Duan L, Wang X, Li Y, Xu C, Liu C, Zhang Y, Zhou W, Liu J, et al: Biological functions and theranostic potential of HMGB family members in human cancers. Ther Adv Med Oncol. 12:17588359209708502020. View Article : Google Scholar : PubMed/NCBI | |
|
Taniguchi N, Kawakami Y, Maruyama I and Lotz M: HMGB proteins and arthritis. Hum Cell. 31:1–9. 2018. View Article : Google Scholar | |
|
Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P and Venereau E: High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 280:74–82. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng KJ, Alshawsh MA, Mejia Mohamed EH, Thavagnanam S, Sinniah A and Ibrahim ZA: HMGB1: An overview of its versatile roles in the pathogenesis of colorectal cancer. Cell Oncol (Dordr). 43:177–193. 2020. View Article : Google Scholar | |
|
Liu L, Liu S, Luo H, Chen C, Zhang X, He L and Tu G: GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells. Aging. 13:16178–16197. 2021. View Article : Google Scholar | |
|
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu J, Liu S, Yu M, Chen J, Wang S, et al: An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target Ther. 6:4212021. View Article : Google Scholar : PubMed/NCBI | |
|
Chai W, Ye F, Zeng L, Li Y and Yang L: HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells. J Exp Clin Cancer Res. 38:3252019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D, Wang Y, Yu R and Zhou X: YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 40:992021. View Article : Google Scholar : PubMed/NCBI | |
|
Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, Lerho T, Bruyere D, Lebeau A, Radermecker C, et al: Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 9:e0019662021. View Article : Google Scholar : PubMed/NCBI | |
|
Zha C, Meng X, Li L, Mi S, Qian D, Li Z, Wu P, Hu S, Zhao S, Cai J and Liu Y: Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis. Cancer Biol Med. 17:154–168. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chou YE, Yang PJ, Lin CY, Chen YY, Chiang WL, Lin PX, Huang ZY, Huang M, Ho YC and Yang SF: The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics. Int J Environ Res Public Health. 17:13322020. View Article : Google Scholar | |
|
Wang JB, Li P, Liu XL, Zheng QL, Ma YB, Zhao YJ, Xie JW, Lin JX, Lu J, Chen QY, et al: An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nat Commun. 11:63522020. View Article : Google Scholar : PubMed/NCBI | |
|
Kam NW, Wu KC, Dai W, Wang Y, Yan LYC, Shakya R, Khanna R, Qin Y, Law S, Lo AWI, et al: Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma. Angiogenesis. 25:181–203. 2022. View Article : Google Scholar | |
|
Gong W, Zheng Y, Chao F, Li Y, Xu Z, Huang G, Gao X, Li S and He F: The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail. J Biomed Biotechnol. 2010:9152342010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S and Zhang Y: HMGB1 in inflammation and cancer. J Hematol Oncol. 13:1162020. View Article : Google Scholar : PubMed/NCBI | |
|
Huebener P, Gwak GY, Pradere JP, Quinzii CM, Friedman R, Lin CS, Trent CM, Mederacke I, Zhao E, Dapito DH, et al: High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo. Cell Metab. 19:539–547. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rapoport BL, Steel HC, Theron AJ, Heyman L, Smit T, Ramdas Y and Anderson R: High mobility group Box 1 in human cancer. Cells. 9:16642020. View Article : Google Scholar : PubMed/NCBI | |
|
Kang R, Zhang Q, Zeh HJ III, Lotze MT and Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res. 19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Amornsupak K, Thongchot S, Thinyakul C, Box C, Hedayat S, Thuwajit P, Eccles SA and Thuwajit C: HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells. BMC Cancer. 22:5782022. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Wang GZ, Wang Y, Huang HZ, Li WT and Qu XD: Hypoxia-induced HMGB1 expression of HCC promotes tumor invasiveness and metastasis via regulating macrophage-derived IL-6. Exp Cell Res. 367:81–88. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hernandez C, Huebener P, Pradere JP, Antoine DJ, Friedman RA and Schwabe RF: HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest. 128:2436–2451. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Wang J, Li J, Zhou X, Yin L, Wang Y, Gu Y, Niu X, Yang Y, Ji H and Zhang Q: HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer. Cancer Sci. 112:1603–1613. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tan G, Huang C, Chen J and Zhi F: HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway. J Hematol Oncol. 13:1492020. View Article : Google Scholar : PubMed/NCBI | |
|
Li Pomi F, Borgia F, Custurone P, Vaccaro M, Pioggia G and Gangemi S: Role of HMGB1 in Cutaneous Melanoma: State of the Art. Int J Mol Sci. 23:93272022. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, Huang L, Yang Y, Zhou B, Yue D, et al: Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 7:422019. View Article : Google Scholar | |
|
Zhang X, Shi H, Yuan X, Jiang P, Qian H and Xu W: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 17:1462018. View Article : Google Scholar : PubMed/NCBI | |
|
Ye F, Chai W, Xie M, Yang M, Yu Y, Cao L and Yang L: HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells. Am J Cancer Res. 9:730–739. 2019.PubMed/NCBI | |
|
Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, Lotze M, Tang D and Tsung A: Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 63:114–121. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liang L, Fu J, Wang S, Cen H, Zhang L, Mandukhail SR, Du L, Wu Q, Zhang P and Yu X: MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B. 10:1036–1046. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Cai L, Guo X, Li Z, Liao X, Zhang X, Huang L and He J: HMGB1-activated fibroblasts promote breast cancer cells metastasis via RAGE/aerobic glycolysis. Neoplasma. 68:71–78. 2021. View Article : Google Scholar | |
|
Lee HJ, Kim A, Song IH, Park IA, Yu JH, Ahn JH and Gong G: Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. Pathol Int. 66:202–209. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan S, Liu Z, Xu Z, Liu J and Zhang J: High mobility group box 1 (HMGB1): A pivotal regulator of hematopoietic malignancies. J Hematol Oncol. 13:912020. View Article : Google Scholar : PubMed/NCBI | |
|
Yasinska IM, Gonçalves Silva I, Sakhnevych SS, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Bardelli M, Varani L, et al: High mobility group box 1 (HMGB1) acts as an 'alarmin' to promote acute myeloid leukaemia progression. Oncoimmunology. 7:e14381092018. View Article : Google Scholar | |
|
Liu L, Zhang J, Zhang X, Cheng P, Liu L, Huang Q, Liu H, Ren S, Wei P, Wang C, et al: HMGB1: An important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. J Mol Med (Berl). 99:107–118. 2021. View Article : Google Scholar | |
|
Zhao M, Yang M, Yang L, Yu Y, Xie M, Zhu S, Kang R, Tang D, Jiang Z, Yuan W, et al: HMGB1 regulates autophagy through increasing transcriptional activities of JNK and ERK in human myeloid leukemia cells. BMB Rep. 44:601–606. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ding C, Yu H, Shi C, Shi T, Qin H and Cui Y: MiR-let-7e inhibits invasion and magration and regulates HMGB1 expression in papillary thyroid carcinoma. Biomed Pharmacother. 110:528–536. 2019. View Article : Google Scholar | |
|
Wang CQ, Huang BF, Wang Y, Tang CH, Jin HC, Shao F, Shao JK, Wang Q and Zeng Y: Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis. Sci Rep. 10:185872020. View Article : Google Scholar : PubMed/NCBI | |
|
Qian F, Xiao J, Gai L and Zhu J: HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to drive colorectal cancer stemness and development. Mol Carcinog. 58:500–510. 2019. View Article : Google Scholar | |
|
Zhang JL, Zheng HF, Li K and Zhu YP: miR-495-3p depresses cell proliferation and migration by downregulating HMGB1 in colorectal cancer. World J Surg Oncol. 20:1012022. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Wang W, Chen Y, Liu X, Wang J, Qin X, Yuan D, Yu T, Chen G, Mi Y, et al: High mobility group box Protein 1 serves as a potential prognostic marker of lung cancer and promotes its invasion and metastasis by matrix Metalloproteinase-2 in a nuclear Factor-κB-dependent manner. Biomed Res Int. 2018:34537062018. | |
|
Zhou Y, Liu SX, Zhou YN, Wang J and Ji R: Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus. Eur Rev Med Pharmacol Sci. 25:1339–1350. 2021.PubMed/NCBI | |
|
van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA and Griffioen AW: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 32:363–374. 2013. View Article : Google Scholar | |
|
van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 11:91–99. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu L, Li X, Chen Y, Fang J and Ge Z: High-mobility group box 1: A novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett. 357:527–534. 2015. View Article : Google Scholar | |
|
Kuniyasu H, Chihara Y and Kondo H: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 104:722–727. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Evans A and Hemers E: Mesenchymal-epithelial signalling in tumour microenvironment: Role of high-mobility group Box 1. Cell Tissue Res. 365:357–366. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar | |
|
Liu PL, Liu WL, Chang JM, Chen YH, Liu YP, Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS One. 12:e01808442017. View Article : Google Scholar : PubMed/NCBI | |
|
Yao S, Zhao T and Jin H: Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer. Biomed Pharmacother. 70:72–79. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Chen X, Gilvary DL, Tejera MM, Eksioglu EA, Wei S and Djeu JY: HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep. 5:150852015. View Article : Google Scholar : PubMed/NCBI | |
|
Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B and Liu B: Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: A revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar : PubMed/NCBI | |
|
Bahar E, Han SY, Kim JY and Yoon H: Chemotherapy resistance: Role of mitochondrial and autophagic components. Cancers (Basel). 14:14622022. View Article : Google Scholar : PubMed/NCBI | |
|
Ge R, Liu L, Dai W, Zhang W, Yang Y, Wang H, Shi Q, Guo S, Yi X, Wang G, et al: Xeroderma pigmentosum Group A promotes autophagy to facilitate cisplatin resistance in melanoma cells through the activation of PARP1. J Invest Dermatol. 136:1219–1228. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira PMP, Sousa RWR, Ferreira JRO, Militão GCG and Bezerra DP: Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. Pharmacol Res. 168:1055822021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JS, Lee JM, Chwae YJ, Kim YH, Lee JH, Kim K, Lee TH, Kim SJ and Park JH: Cisplatin-induced apoptosis in Hep3B cells: Mitochondria-dependent and -independent pathways. Biochem Pharmacol. 67:1459–1468. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Çoku J, Booth DM, Skoda J, Pedrotty MC, Vogel J, Liu K, Vu A, Carpenter EL, Ye JC, Chen MA, et al: Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO J. 41:e1082722022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Liu L, Xie M, Sun X, Yu Y, Kang R, Yang L, Zhu S, Cao L and Tang D: Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy. 11:214–224. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pal Singh M, Pal Khaket T, Bajpai VK, Alfarraj S, Kim SG, Chen L, Huh YS, Han YK and Kang SC: Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy. Int J Mol Sci. 21:82532020. View Article : Google Scholar : PubMed/NCBI | |
|
Tang D, Loze MT, Zeh HJ and Kang R: The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy. 6:1181–1183. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III and Lotze MT: Endogenous HMGB1 regulates autophagy. J Cell Biol. 190:881–892. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III and Lotze MT: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Singh MP, Cho HJ, Kim JT, Baek KE, Lee HG and Kang SC: Morin hydrate reverses cisplatin resistance by impairing PARP1/HMGB1-dependent autophagy in hepatocellular carcinoma. Cancers (Basel). 11:9862019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Q, Wang Y, Dong W, Song E and Song Y: Polychlorinated biphenyl quinone-induced signaling transition from autophagy to apoptosis is regulated by HMGB1 and p53 in human hepatoma HepG2 cells. Toxicol Lett. 306:25–34. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Gong W, Lu L, Wang Y and Ren J: Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells. Braz J Med Biol Res. 52:e86572019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Chu X and Wei Q: MiR-451 promotes cell apoptosis and inhibits autophagy in pediatric acute myeloid leukemia by targeting HMGB1. J Environ Pathol Toxicol Oncol. 40:45–53. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Run L, Wang L, Nong X, Li N, Huang X and Xiao Y: Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy. Endocrine. 71:418–426. 2021. View Article : Google Scholar | |
|
Mou K, Liu W, Han D and Li P: HMGB1/RAGE axis promotes autophagy and protects keratinocytes from ultraviolet radiation-induced cell death. J Dermatol Sci. 85:162–169. 2017. View Article : Google Scholar | |
|
Li H, Li J, Zhang G, Da Q, Chen L, Yu S, Zhou Q, Weng Z, Xin Z, Shi L, et al: HMGB1-induced p62 overexpression promotes snail-mediated epithelial-mesenchymal transition in glioblastoma cells via the degradation of GSK-3β. Theranostics. 9:1909–1922. 2019. View Article : Google Scholar : | |
|
Liu W, Zhang Z, Zhang Y, Chen X, Guo S, Lei Y, Xu Y, Ji C, Bi Z and Wang K: HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol Ther. 16:511–517. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SY, Hsu YH, Wang SY, Chen YY, Hong CJ and Yen GC: Lucidone inhibits autophagy and MDR1 via HMGB1/RAGE/PI3K/Akt signaling pathway in pancreatic cancer cells. Phytother Res. 36:1664–1677. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma S, Yang B and He Q: HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy. 14:2155–2170. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao JY and Dixon SJ: Mechanisms of ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liang C, Zhang X, Yang M and Dong X: Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI | |
|
Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA and Lei P: Ferroptosis: Mechanisms and links with diseases. Signal Transduct Target Ther. 6:492021. View Article : Google Scholar : PubMed/NCBI | |
|
Hassannia B, Vandenabeele P and Vanden Berghe T: Targeting ferroptosis to Iron out cancer. Cancer Cell. 35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Stockwell BR: Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H and ME LL: Oxidative stress and cancer: An overview. Ageing Res Rev. 12:376–390. 2013. View Article : Google Scholar | |
|
Wang D, Tang L, Zhang Y, Ge G, Jiang X, Mo Y, Wu P, Deng X, Li L, Zuo S, et al: Regulatory pathways and drugs associated with ferroptosis in tumors. Cell Death Dis. 13:5442022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Kang R and Tang D: The mechanism of HMGB1 secretion and release. Exp Mol Med. 54:91–102. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wen Q, Liu J, Kang R, Zhou B and Tang D: The release and activity of HMGB1 in ferroptosis. Biochem Biophys Res Commun. 510:278–283. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wiernicki B, Maschalidi S, Pinney J, Adjemian S, Vanden Berghe T, Ravichandran KS and Vandenabeele P: Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun. 13:36762022. View Article : Google Scholar : PubMed/NCBI | |
|
Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C, Bachert C, Coppieters F, et al: Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 8:e0013692020. View Article : Google Scholar : PubMed/NCBI | |
|
Vats K, Kruglov O, Mizes A, Samovich SN, Amoscato AA, Tyurin VA, Tyurina YY, Kagan VE and Bunimovich YL: Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 47:1021432021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Wang Z, Liu Z, Du K and Lu X: Protective effects of dexazoxane on rat ferroptosis in doxorubicin-induced cardiomyopathy through regulating HMGB1. Front Cardiovasc Med. 8:6854342021. View Article : Google Scholar : PubMed/NCBI | |
|
Friedmann Angeli JP, Krysko DV and Conrad M: Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 19:405–414. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhary N, Choudhary BS, Shah SG, Khapare N, Dwivedi N, Gaikwad A, Joshi N, Raichanna J, Basu S, Gurjar M, et al: Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer. Int J Cancer. 149:1495–1511. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
You JH, Lee J and Roh JL: PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells. J Exp Clin Cancer Res. 40:3502021. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, You JH, Shin D and Roh JL: Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant head and neck cancer cells to ferroptosis. Theranostics. 10:7775–7786. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Wang S, Yu G and Chen X: Cell death mediated by the pyroptosis pathway with the aid of nanotechnology: Prospects for cancer therapy. Angew Chem Int Ed Engl. 60:8018–8034. 2021. View Article : Google Scholar | |
|
Qi S, Wang Q, Zhang J, Liu Q and Li C: Pyroptosis and its role in the modulation of cancer progression and antitumor immunity. Int J Mol Sci. 23:104942022. View Article : Google Scholar : PubMed/NCBI | |
|
Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, Kiessling F and Ries CH: Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 70:1280–1297. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu LS, Liu Y, Wang XW, Xu B, Lin YL, Song Y, Dong Y, Liu JL, Wang XJ, Liu S, et al: LPS enhances the chemosensitivity of oxaliplatin in HT29 cells via GSDMD-mediated pyroptosis. Cancer Manag Res. 12:10397–10409. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Z, Ji L, Han M, Xie J, Zhong F, Zhang X, Su Q, Yang Z, Liu Z, Gao H and Jiang G: Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer. Life Sci. 257:1180652020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, Wang K, Sun X and Zheng J: Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 10:1932019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Liu W, Ning J, Wang J, Lang Y, Jin X, Zhu K, Wang X, Li X, Yang F, et al: Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. Int J Biol Sci. 14:406–417. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Lu H, Pan Y, Liu C, Wang J, Chen B and Wang Y: The role of pyroptosis and its crosstalk with immune therapy in breast cancer. Front Immunol. 13:9739352022. View Article : Google Scholar : PubMed/NCBI | |
|
Yu P, Zhang X, Liu N, Tang L, Peng C and Chen X: Pyroptosis: Mechanisms and diseases. Signal Transduct Target Ther. 6:1282021. View Article : Google Scholar : PubMed/NCBI | |
|
Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J and Hu J: The role of pyroptosis in cancer: Pro-cancer or pro-'host'? Cell Death Dis. 10:6502019. View Article : Google Scholar | |
|
Volchuk A, Ye A, Chi L, Steinberg BE and Goldenberg NM: Indirect regulation of HMGB1 release by gasdermin D. Nat Commun. 11:45612020. View Article : Google Scholar : PubMed/NCBI | |
|
Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, Zhao X, Liu J, Tang C, Liu Z, et al: The endotoxin delivery protein HMGB1 mediates Caspase-11-dependent lethality in sepsis. Immunity. 49:740–753.e7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hou W, Wei X, Liang J, Fang P, Ma C, Zhang Q and Gao Y: HMGB1-induced hepatocyte pyroptosis expanding inflammatory responses contributes to the pathogenesis of Acute-on-chronic liver failure (ACLF). J Inflamm Res. 14:7295–7313. 2021. View Article : Google Scholar | |
|
Peng Z, Wang P, Song W, Yao Q, Li Y, Liu L, Li Y and Zhou S: GSDME enhances Cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antitumor immunocyte infiltration. Signal Transduct Target Ther. 5:1592020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi F, Zhang L, Liu X and Wang Y: Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death. Bioengineered. 12:6332–6342. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES and Aplin AE: Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 10:254–269. 2020. View Article : Google Scholar : | |
|
Chen B, Dragomir MP, Yang C, Li Q, Horst D and Calin GA: Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 7:1212022. View Article : Google Scholar : PubMed/NCBI | |
|
Barth DA, Drula R, Ott L, Fabris L, Slaby O, Calin GA and Pichler M: Circulating Non-coding RNAs in renal cell carcinoma-pathogenesis and potential implications as clinical biomarkers. Front Cell Dev Biol. 8:8282020. View Article : Google Scholar : PubMed/NCBI | |
|
Zeuschner P, Linxweiler J and Junker K: Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 20:151–167. 2020. View Article : Google Scholar | |
|
Barth DA, Slaby O, Klec C, Juracek J, Drula R, Calin GA and Pichler M: Current concepts of Non-coding RNAs in the pathogenesis of non-clear cell renal cell carcinoma. Cancers (Basel). 11:15802019. View Article : Google Scholar : PubMed/NCBI | |
|
Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell. 27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci. 16:2628–2647. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Taheri M, Shirvani-Farsani Z, Ghafouri-Fard S and Omrani MD: Expression profile of microRNAs in bladder cancer and their application as biomarkers. Biomed Pharmacother. 131:1107032020. View Article : Google Scholar : PubMed/NCBI | |
|
Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, et al: miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer. 13:2342014. View Article : Google Scholar : PubMed/NCBI | |
|
Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E and Teixidó J: miR-204-5p and miR-211-5p Contribute to BRAF inhibitor resistance in melanoma. Cancer Res. 78:1017–1030. 2018. View Article : Google Scholar : | |
|
Sur S and Ray RB: Emerging role of lncRNA ELDR in development and cancer. FEBS J. 289:3011–3023. 2022. View Article : Google Scholar | |
|
Zhu L, Zhu Y, Han S, Chen M, Song P, Dai D, Xu W, Jiang T, Feng L, Shin VY, et al: Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 10:3832019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Y, Zheng S, Wu Q, Wu J, Zhou R, Wang C, Wu Z, Rong X, Huang N, Sun L, et al: Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy. 17:4083–4101. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Xu Y, Xie W, Tang Y, Zhang H, Wang B, Mao J, Rui T, Jiang P and Zhang W: Long noncoding RNA DLGAP1-AS2 facilitates Wnt1 transcription through physically interacting with Six3 and drives the malignancy of gastric cancer. Cell Death Discov. 7:2552021. View Article : Google Scholar : PubMed/NCBI | |
|
Ren C, Han H, Pan J, Chang Q, Wang W, Guo X and Bian J: DLGAP1-AS2 promotes human colorectal cancer progression through trans-activation of Myc. Mamm Genome. 33:672–683. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Sun H, Luo D, Gan L, Mo S, Dai W, Liang L, Yang Y, Xu M, Li J, et al: Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids. J Exp Clin Cancer Res. 40:3482021. View Article : Google Scholar | |
|
Chioccarelli T, Falco G, Cappetta D, De Angelis A, Roberto L, Addeo M, Ragusa M, Barbagallo D, Berrino L, Purrello M, et al: FUS driven circCNOT6L biogenesis in mouse and human spermatozoa supports zygote development. Cell Mol Life Sci. 79:502021. View Article : Google Scholar : PubMed/NCBI | |
|
Singh V, Uddin MH, Zonder JA, Azmi AS and Balasubramanian SK: Circular RNAs in acute myeloid leukemia. Mol Cancer. 20:1492021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, Song K and Xu RH: The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. 20:1662021. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Song R, Yin F, Liu M, Liu H, Ma S, Jia X, Lu X, Zhong Y, Yu L, et al: circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma. Mol Ther. 30:431–447. 2022. View Article : Google Scholar : | |
|
Zhang Y, Liu Y and Xu X: Upregulation of miR-142-3p improves drug sensitivity of acute myelogenous leukemia through reducing P-glycoprotein and repressing autophagy by targeting HMGB1. Transl Oncol. 10:410–418. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO and Davies L: Evaluation of gender inequity in thyroid cancer diagnosis: Differences by Sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Internal Med. 181:1351–1358. 2021. View Article : Google Scholar | |
|
Lei T, Huang J, Xie F, Gu J, Cheng Z and Wang Z: HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 54:fpage–lpage. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kishi S, Fujiwara-Tani R, Honoki K, Sasaki R, Mori S, Ohmori H, Sasaki T, Miyagawa Y, Kawahara I, Kido A, et al: Oxidized high mobility group B-1 enhances metastability of colorectal cancer via modification of mesenchymal stem/stromal cells. Cancer Sci. 113:2904–2915. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ren Y, Cao L, Wang L, Zheng S, Zhang Q, Guo X, Li X, Chen M, Wu X, Furlong F, et al: Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling. Cell Death Dis. 12:8582021. View Article : Google Scholar | |
|
Ning J, Yang R, Wang H and Cui L: HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-κB pathway. Exp Ther Med. 22:7052021. View Article : Google Scholar | |
|
Zhou P, Zheng ZH, Wan T, Wu J, Liao CW and Sun XJ: Vitexin inhibits gastric cancer growth and metastasis through HMGB1-mediated inactivation of the PI3K/AKT/mTOR/HIF-1α signaling pathway. J Gastric Cancer. 21:439–456. 2021. View Article : Google Scholar | |
|
Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X and Fan X: VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. J Transl Med. 20:2122022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zou N, Deng W, Song C, Yan K, Shen W and Zhu S: HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma. Mol Biol Rep. 49:11933–11945. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng MY, Liu ZJ, Chen JB, Li K, Sun SK, et al: Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. J Nanobiotechnol. 19:2682021. View Article : Google Scholar | |
|
Yang L, Yu Y, Kang R, Yang M, Xie M, Wang Z, Tang D, Zhao M, Liu L, Zhang H and Cao L: Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma. 53:315–322. 2012. View Article : Google Scholar | |
|
Liu N, Wu Y, Wen X, Li P, Lu F and Shang H: Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1β signaling pathway. J Mol Med (Berl). 99:403–414. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H, Guo H, Sun S, Li M, Zhao D, et al: Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chin Med. 17:902022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei J, Liu Z, He J, Liu Q, Lu Y, He S, Yuan B, Zhang J and Ding Y: Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism. Clin Transl Oncol. 24:471–482. 2022. View Article : Google Scholar | |
|
Xi S, Peng Y, Minuk GY, Shi M, Fu B, Yang J, Li Q, Gong Y, Yue L, Li L, et al: The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy. J Ethnopharmacol. 190:1–12. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Li Y, Lu J, Qiu M, Cheng D, Zhang X and Yuan W: Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice. Biomed Pharmacother. 140:1117752021. View Article : Google Scholar : PubMed/NCBI | |
|
Xi S, Zhai X, Wang Y, Gong Y, Fu B, Gao C, Guo X, Li Y, Wang Z, Huang S, et al: The Ciji-Hua'ai-Baosheng II formula attenuates chemotherapy-induced anorexia in mice with H22 hepatocellular carcinoma. Front Pharmacol. 12:7158242021. View Article : Google Scholar | |
|
Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, et al: Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin. 42:301–310. 2021. View Article : Google Scholar : | |
|
Ming JX, Wang ZC, Huang Y, Ohishi H, Wu RJ, Shao Y, Wang H, Qin MY, Wu ZL, Li YY, et al: Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. J Ethnopharmacol. 265:1133022021. View Article : Google Scholar | |
|
Li Y, Liu T, Li Y, Han D, Hong J, Yang N, He J, Peng R, Mi X, Kuang C, et al: Baicalin ameliorates cognitive impairment and protects microglia from LPS-induced neuroinflammation via the SIRT1/HMGB1 pathway. Oxid Med Cell Longev. 2020:47513492020. View Article : Google Scholar : PubMed/NCBI | |
|
Yan G, Chen L, Wang H, Wu S, Li S and Wang X: Baicalin inhibits LPS-induced inflammation in RAW264.7 cells through miR-181b/HMGB1/TRL4/NF-κB pathway. Am J Transl Res. 13:10127–10141. 2021. | |
|
Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG and Li J: Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J Exp Clin Cancer Res. 38:2542019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Chen W, Li Y, Zhang S, Lou H, Lu X and Fan X: Reduning injection and its effective constituent luteoloside protect against sepsis partly via inhibition of HMGB1/TLR4/NF-κB/MAPKs signaling pathways. J Ethnopharmacol. 270:1137832021. View Article : Google Scholar | |
|
Wei X, Zhang B, Wei F, Ding M, Luo Z, Han X and Tan X: Gegen Qinlian pills alleviate carrageenan-induced thrombosis in mice model by regulating the HMGB1/NF-κB/NLRP3 signaling. Phytomedicine. 100:1540832022. View Article : Google Scholar | |
|
Roy M, Liang L, Xiao X, Peng Y, Luo Y, Zhou W, Zhang J, Qiu L, Zhang S, Liu F, et al: Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma. Theranostics. 6:2209–2224. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yu AM, Jian C, Yu AH and Tu MJ: RNA therapy: Are we using the right molecules? Pharmacol Ther. 196:91–104. 2019. View Article : Google Scholar : | |
|
Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ngamcherdtrakul W and Yantasee W: siRNA therapeutics for breast cancer: Recent efforts in targeting metastasis, drug resistance, and immune evasion. Transl Res. 214:105–120. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Yadav P, Sundaram S, Venkatraman G, Bera AK and Karunagaran D: HMGB3 inhibition by miR-142-3p/sh-RNA modulates autophagy and induces apoptosis via ROS accumulation and mitochondrial dysfunction and reduces the tumorigenic potential of human breast cancer cells. Life Sci. 304:1207272022. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Yadav P, Jain RP, Bera AK and Karunagaran D: miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells. Life Sci. 291:1202682022. View Article : Google Scholar : PubMed/NCBI | |
|
Mukherjee A and Vasquez KM: Targeting chromosomal architectural HMGB proteins could be the next frontier in cancer therapy. Cancer Res. 80:2075–2082. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu T, Zhang W, Yang G, Li H, Chen Q, Song R and Zhao L: HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review. Oncotarget. 7:50417–50427. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xie J, Yang Y, Gao Y and He J: Cuproptosis: Mechanisms and links with cancers. Mol Cancer. 22:462023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Liu Y, Wang Y, Kang R and Tang D: HMGB1 is a mediator of cuproptosis-related sterile inflammation. Front Cell Dev Biol. 10:9963072022. View Article : Google Scholar : PubMed/NCBI | |
|
Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayır H, Abhari BA, Angeli JPF, Choi SM, et al: Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Invest. 128:3341–3355. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KS, Choi B, Choi H, Ko MJ and Kim DH and Kim DH: Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer. J Nanobiotechnol. 20:4282022. View Article : Google Scholar | |
|
Zheng X, Zhao Y, Jia Y, Shao D, Zhang F, Sun M, Dawulieti J, Hu H, Cui L, Pan Y, et al: Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials. 271:1207162021. View Article : Google Scholar : PubMed/NCBI | |
|
Meng X, Lou QY, Yang WY, Wang YR, Chen R, Wang L, Xu T and Zhang L: The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond). 41:981–1006. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang T, Qiao Y, Ruan W, Zhang D, Yang Q, Wang G, Chen Q, Zhu F, Yin J, Zou Y, et al: Cation-free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Adv Mater. 33:e21047792021. View Article : Google Scholar : PubMed/NCBI | |
|
Fu S, Li G, Zang W, Zhou X, Shi K and Zhai Y: Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy. Acta Pharm Sin B. 12:92–106. 2022. View Article : Google Scholar : PubMed/NCBI |
